SCHEMBL686435

SCHEMBL686435

COC(C(C)=O)(c1ccccc1)C(F)(F)F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 1/20 0.44
KCNN4 O15554 1/20 0.44
NR1H2 P55055 3/20 0.41
NR1H3 Q13133 3/20 0.41
ENPP2 Q13822 2/20 0.39
PTPN1 P18031 1/20 0.38
MAPT P10636 3/20 0.37
KMT2A Q03164 1/20 0.37
NPC1 O15118 1/20 0.37
MAPK1 P28482 1/20 0.37
RAB9A P51151 1/20 0.37
ALDH1A1 P00352 4/20 0.37
TSHR P16473 2/20 0.37
CYP2C19 P33261 1/20 0.36
HIF1A Q16665 1/20 0.36
LMNA P02545 2/20 0.36
KDM4E B2RXH2 1/20 0.36
TP53 P04637 1/20 0.36
BACE1 P56817 1/20 0.36
CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL464445 1.00 CES1 (0.44) CES1KCNN4NR1H2NR1H3ENPP2
SCHEMBL12341938 1.00 CES1 (0.44) CES1KCNN4NR1H2NR1H3ENPP2
SCHEMBL236358 0.89 CES1 (0.47) CES1KCNN4NR1H2NR1H3ENPP2
SCHEMBL246914 0.89 CES1 (0.47) CES1KCNN4NR1H2NR1H3ENPP2
SCHEMBL236357 0.89 CES1 (0.47) CES1KCNN4NR1H2NR1H3ENPP2
Hydrochloric Acid SCHEMBL4926039 0.87 CES1 (0.46) CES1KCNN4NR1H2NR1H3ENPP2
Hydrochloric Acid SCHEMBL5595770 0.87 CES1 (0.46) CES1KCNN4NR1H2NR1H3ENPP2
Hydrochloric Acid SCHEMBL8829227 0.87 CES1 (0.46) CES1KCNN4NR1H2NR1H3ENPP2
SCHEMBL7436744 0.85 CES1 (0.44) CES1KCNN4NR1H2NR1H3ENPP2
SCHEMBL13316436 0.84 CES1 (0.43) CES1KCNN4NR1H2NR1H3ENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10017499-B2 Benzimidazole derivatives ENANTA PHARMACEUTICALS, INC. (US) 2018-07-10 US disclosed
EP-3019196-B1 COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-06-06 EP disclosed
EP-2802326-B1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-04-18 EP disclosed
US-8957056-B2 Migrastatin analogs in the treatment of cancer SLOAN-KETTERING INSTIUTE FOR CANCER RESEARCH (US) 2015-02-17 US disclosed
US-8835693-B2 Migrastatin analogs and uses thereof SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2014-09-16 US disclosed
US-20140011844-A1 MIGRASTATIN ANALOGS AND USES THEREOF SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2014-01-09 US disclosed
US-8324284-B2 Migrastatin analogs and uses thereof SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2012-12-04 US disclosed
US-20110281916-A1 MIGRASTATIN ANALOGS AND USES THEREOF SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2011-11-17 US disclosed
US-7943800-B2 Migrastatin analogs and uses thereof SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2011-05-17 US disclosed
US-7741513-B2 Thioacids and thioacid salts for determining the enantiomeric excess of chiral compounds containing an electrophilic carbon center RICHMAN JACK E 2010-06-22 US disclosed
US-20090181462-A1 Thioacids and thioacid salts for determining the enantiomeric excess of chiral compounds containing an electrophilic carbon center RICHMAN JACK E 2009-07-16 US disclosed
US-20070037852-A1 Migrastatin analogs and uses thereof NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2007-02-15 US disclosed
US-20070037783-A1 Migrastatin analogs and uses thereof NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2007-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037783-A1 Migrastatin analogs and uses thereof FOXM1, MTX1, C3AR1 CES1 277/4885KCNN4 2222/4885NR1H2 96/4885
US-10017499-B2 Benzimidazole derivatives EIF2AK2, ZC3HAV1, ZC3HAV1L CES1 79/4885KCNN4 4536/4885NR1H2 1143/4885
US-20110281916-A1 MIGRASTATIN ANALOGS AND USES THEREOF KDR, HMGCR, LPAR3 CES1 794/4885KCNN4 3138/4885NR1H2 167/4885
US-20070037852-A1 Migrastatin analogs and uses thereof KDR, MTX1, FOXM1 CES1 651/4885KCNN4 3202/4885NR1H2 129/4885
US-20140011844-A1 MIGRASTATIN ANALOGS AND USES THEREOF KDR, HMGCR, LPAR3 CES1 794/4885KCNN4 3138/4885NR1H2 167/4885
US-20090181462-A1 Thioacids and thioacid salts for determining the enantiomeric excess of chiral compounds containing an electrophilic carbon center TST, SLC6A6, MPST CES1 608/4885KCNN4 1498/4885NR1H2 4175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.